中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

干扰素λ3在慢性乙型肝炎患者血清中的表达及临床意义

段元丽 管世鹤 杨凯 陈礼文 张浩 王秀 潘正兰 侯舒文 王兆飞

引用本文:
Citation:

干扰素λ3在慢性乙型肝炎患者血清中的表达及临床意义

DOI: 10.3969/j.issn.1001-5256.2019.02.014
基金项目: 

安徽省科技厅重点研究与开发计划项目(1804h08020236); 安徽省高校自然科学研究项目(KJ2018A0206); 

详细信息
  • 中图分类号: R512.62

Serum level of interferon-λ3 in patients with chronic hepatitis B and its clinical significance

Research funding: 

 

  • 摘要:

    目的了解慢性乙型肝炎患者血清IFNλ3水平,探究其临床意义及其与核苷和核苷酸类药物治疗的关系。方法选取2017年1月-2018年5月在安徽医科大学第二附属医院就诊的慢性乙型肝炎患者119例,收集同期HBsAg阴性的22例健康体检者作为健康对照。采用ELISA法检测血清中IFNλ3的表达水平,比较慢性乙型肝炎患者与健康人血清IFNλ3水平差异,分析慢性乙型肝炎患者血清IFNλ3水平与HBeAg的关系,观察不同核苷和核苷酸类药物治疗慢性乙型肝炎患者的血清IFNλ3水平,以及核苷和核苷酸类药物对外周血单个核细胞培养上清中IFNλ3水平的影响。满足正态性和方差齐性的计量资料多组间比较采用方差分析;对非正态或方差不齐的计量资料,两组比较采用Wilcoxon秩和检验,多组比较采用Kruskal-Wallis H检验,进一步两两比较采用Nemenyi法检验。相关性分析用Spearman相关性分析法。结果慢性乙型肝炎患者血清IFNλ3水平明显低于健康对照组[14. 7(5. 9~28. 5) pg/ml vs 76. 1(39. 4~112. 0) pg/ml,Z=-10. 114,P <0. ...

     

  • [1]WANG WJ, XIE Q.Challenges and strategies of antiviral therapy for chronic hepatitis B-how to achieve the maximization of clinical cure?[J].J Clin Hepatol, 2017, 33 (8) :1415-1418. (in Chinese) 王伟静, 谢青.慢性乙型肝炎抗病毒治疗的挑战与策略---如何实现临床治愈最大化[J].临床肝胆病杂志, 2017, 33 (8) :1415-1418.
    [2]PAPATHEODORIDIS GV, LAMPERTICO P, MANOLAKOPOU-LOS S, et al.Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos (t) ide therapy:A systematic review[J].J Hepatol, 2010, 53 (2) :348-356.
    [3]WONG LH, CHAN LY, MAK WH, et al.Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis[J].Hepatology, 2013, 58 (5) :1537-1547.
    [4]TRPO C, CHAN HL, LOK A.Hepatitis B virus infection[J].Lancet, 2014, 384 (9959) :2053-2063.
    [5]MARCELLIN P, LAU GK, BONINO F, et al.Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBe Ag-negative chronic hepatitis B[J].N Engl JMed, 2004, 351 (12) :1206-1217.
    [6]QI X.Peginterferon alfa-2a, lamivudine, and the combination for HBe Ag-positive chronic hepatitis B[J].N Engl J Med, 2005, 352 (26) :2682-2695.
    [7]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:A 2015 update[J].JClin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
    [8]HRUSKA M, WANG X, CHAN P, et al.Derivation of phase 3dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2:Exposure-response analyses for efficacy and safety variables[J].J Clin Pharmacol, 2015, 55 (1) :73-80.
    [9]BOLEN CR, DING S, ROBEK MD, et al.Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression[J].Hepatology, 2014, 59 (4) :1262-1272.
    [10]LIAO Y, LI Y, CAI B, et al.Lack of association between IL-28Bpolymorphisms and spontaneous virus clearance in HBV patients[J].Clin Infect Dis, 2013, 75 (9) :409-417.
    [11]SHI X, CHI X, PAN Y, et al.IL-28B is associated with outcomes of chronic HBV infection[J].Yonsei Med J, 2015, 56 (3) :625-633.
    [12]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis B:A 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
    [13]MURATA K, ASANO M, MATSUMOTO A, et al.Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues:A new potential target for HBV infection[J].Gut, 2018, 67 (2) :362-371.
    [14]ZOU HX, WANG JH, CUI HL, et al.The relativity study between abnormal serum markers of hepatitis B and HBV-DNA[J].Int J Virol, 2017, 27 (4) :239-242. (in Chinese) 邹红霞, 王金环, 崔海玲, 等.乙型肝炎异常血清学诊断模式与HBV-DNA载量的相关性研究[J].国际病毒学杂志, 2017, 27 (4) :239-242.
    [15] GONG Q.Clinical significance of combined determination of HBV-DNA、five indicators for hepatitis B and liver function parameters in patients with chronic hepatitis B[J].World Clin Med, 2017, 11 (7) :230. (in Chinese) 龚蔷.HBV-DNA、乙肝两对半和肝功能的联合检测对慢性乙肝患者的临床意义[J].世界临床医学, 2017, 11 (7) :230.
    [16]ABUSHAHBA W, BALAN M, CASTANEDA I, et al.Antitumor activity of type I and type III interferons in BNL hepatoma model[J].Cancer Immunol Immunother, 2010, 59 (7) :1059-1071.
    [17]ISOGAWA M, TANAKA Y.The Immunobiology of hepatitis Bvirus infection[J].Hepatol Res, 2015, 45 (2) :179-189.
    [18]KOTENKO SV.IFN-λs[J].Curr Opin Immunol, 2011, 23 (5) :583-590.
    [19]SOMMEREYNS C, PAUL S, STAEHELI P, et al.IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo[J].PLo S Pathog, 2008, 4 (3) :e1000017.
    [20]van der MOLEN RG, SPRENGERS D, BIESTA PJ, et al.Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV[J].Hepatology, 2010, 44 (4) :907-914.
    [21]YOU J, CHEN J, YE QX, et al.Efficacy of add-on adefovir dipivoxil at week 12/24 in HBe Ag-positive chronic hepatitis Bpatients during PEG-IFN-αtherapy[J].J Clin Hepatol, 2016, 32 (4) :687-690. (in Chinese) 游佳, 陈靖, 叶巧霞, 等.聚乙二醇干扰素α加用阿德福韦酯治疗HBe Ag阳性慢性乙型肝炎的效果观察[J].临床肝胆病杂志, 2016, 32 (4) :687-690.
    [22]XIE Q, ZHOU H, BAI X, et al.A randomized, open-label clinical study of combined pegylated interferon alfa-2a (40KD) and entecavir treatment for hepatitis B"e"antigenpositive chronic hepatitis B[J].Clin Infect Dis, 2014, 59 (12) :1714-1723.
  • 加载中
计量
  • 文章访问数:  1600
  • HTML全文浏览量:  32
  • PDF下载量:  310
  • 被引次数: 0
出版历程
  • 出版日期:  2019-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回